logo
  

Orion: Phase III Trial With Darolutamide Meets Primary Endpoint In MHSPC

Orion Oyj announced Orion's and Bayer's (BAYZF.PK,BAYRY.PK,BYR.L) phase III ARASENS trial showed an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy compared to docetaxel and androgen deprivation therapy, a standard of care in metastatic hormone-sensitive prostate cancer. The overall incidence of reported adverse events was similar between treatment arms, the company said.

Bayer plans to discuss the data from ARASENS with health authorities worldwide regarding the submission for marketing authorisation in this indication.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT